10-Q: Quarterly report
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on "Therapeutic Over-Activation in Cancer"
Express News | Lixte Biotechnology Holdings Files $50M Offering
Express News | Lixte Biotechnology Holdings Inc Files for Mixed Shelf Offering of up to $50 Mln- SEC Filing
Express News | Watching Lixte Biotechnology; White Diamond Research Posts On X "BREAKING NEWS: Lixte Biotechnology Lied: Its Publication Yesterday Isn't New – It's The Same One They Published Over A Year Ago"
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks were rising late Wednesday afternoon, with the NYSE Health Care Index adding 0.8% and the Health Care Select Sector SPDR Fund (XLV) climbing 1%. The iShares Biotechnology ETF (IBB)
Top Midday Gainers
iBio's (IBIO) shares were up 211% amid heavy trading Wednesday, a day after the company said it signed a securities purchase agreement for a private investment in public equity financing with expected
SMR, GCTS and GSIW Among Mid-day Movers
Why Lixte Biotechnology Stock Is Soaring
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares are trading higher Wednesday after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100.The Details:
IBio, ImmunityBio, Mesoblast Among Healthcare Movers
Dow Jumps Over 200 Points; UniFirst Posts Downbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones gaining over 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.58% to 39,511.62 while the NASDAQ rose 0.60
Express News | LIXTE Shares Are Trading Higher After the Company Announced the Publication of Pre-clinical Data on Its Lead Clinical Compound, LB-100
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersLixte Biotechnology (NASDAQ:LIXT) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.4 million. Nutriband (NASDA
LIXTE Biotechnology Holdings Publication Pre-Clinical Data In Cancer Discovery Regarding LB-100
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS
LIXTE Provides Update on Progress With LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company")
Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research
Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic PASADENA, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, I
Express News | LIXTE Biotechnology Enters Exclusive Immune Oncology Patent License Agreement With NINDS And NCI
LIXTE Biotechnology Enters Into Exclusive Immune Oncology Patent License Agreement With NINDS and NCI
Agreement Focuses on Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the
LIXTE Biotechnology Shares Rise 14% After First Patient Dosed in LB-100 Trial
By Chris Wack LIXTE Biotechnology shares were up 14% to $2.27 after the company said it has dosed the first patient in a Phase 1b/2 clinical trial to assess whether adding LB-100 to GlaxoSmithKline's
Express News | Lixte Biotechnology Announces Dosing Of First Patient In Phase 1b.2 Trial Assessing LIXTE's LB-100 And GSK's Immunotherapy Dostarlimab-gxly In Ovarian Clear Cell Carcinoma Trial
No Data